SONNET BIOTHERAPEUTICS HOLDI (SONN)
US83548R3030 - Common Stock
Taking everything into account, SONN scores 2 out of 10 in our fundamental rating. SONN was compared to 588 industry peers in the Biotechnology industry. While SONN seems to be doing ok healthwise, there are quite some concerns on its profitability. SONN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SONN had negative earnings in the past year.
In the past year SONN has reported a negative cash flow from operations.
SONN had negative earnings in each of the past 5 years.
In the past 5 years SONN always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -271.00%, SONN is doing worse than 93.32% of the companies in the same industry.
With a Return On Equity value of -562.31%, SONN is not doing good in the industry: 80.82% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -271% | ||
| ROE | -562.31% | ||
| ROIC | N/A |
ROA(3y)-314.27%
ROA(5y)-204.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SONN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SONN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SONN has more shares outstanding
The number of shares outstanding for SONN has been increased compared to 5 years ago.
There is no outstanding debt for SONN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
SONN has an Altman-Z score of -36.52. This is a bad value and indicates that SONN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -36.52, SONN is doing worse than 92.12% of the companies in the same industry.
SONN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -36.52 |
ROIC/WACCN/A
WACC9.29%
2.3 Liquidity
SONN has a Current Ratio of 1.74. This is a normal value and indicates that SONN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.74, SONN is doing worse than 79.62% of the companies in the same industry.
A Quick Ratio of 1.74 indicates that SONN should not have too much problems paying its short term obligations.
The Quick ratio of SONN (1.74) is worse than 78.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.74 | ||
| Quick Ratio | 1.74 |
3. Growth
3.1 Past
SONN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 90.73%, which is quite impressive.
Looking at the last year, SONN shows a very negative growth in Revenue. The Revenue has decreased by -47.73% in the last year.
Measured over the past years, SONN shows a very negative growth in Revenue. The Revenue has been decreasing by -67.61% on average per year.
EPS 1Y (TTM)90.73%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q98.24%
Revenue 1Y (TTM)-47.73%
Revenue growth 3Y-83.01%
Revenue growth 5Y-67.61%
Revenue growth Q2Q-53.42%
3.2 Future
Based on estimates for the next years, SONN will show a very strong growth in Earnings Per Share. The EPS will grow by 40.69% on average per year.
SONN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 125.61% yearly.
EPS Next Y95.81%
EPS Next 2Y40.69%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-17.61%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y125.61%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SONN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SONN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SONN's earnings are expected to grow with 40.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.69%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for SONN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SONNET BIOTHERAPEUTICS HOLDI
NASDAQ:SONN (4/25/2024, 7:18:08 PM)
1.76
-0.08 (-4.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.40M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -271% | ||
| ROE | -562.31% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.74 | ||
| Quick Ratio | 1.74 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)90.73%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y95.81%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-47.73%
Revenue growth 3Y-83.01%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y